A landmark study provided by the Ohio State University in Columbus has just been published in the Journal of Cancer Biology & Therapy and the results are consistent with the latest research validating the use of HBOT in Cancer therapy. It has already been well established that solid tumours are low in oxygen (hypoxic) and it is this factor that limits conventional therapy like chemo and radiation, and allows for resistance to congenital treatments. In this study, the addition of HBOT (90 minute sessions daily for up to 21 days at a dose of 2.0 ATA)corrected the hypoxic tumour and leading to enhancement of chemotherapeutic regimen for ovarian cancer. In addition and of extreme significance is that the application of HBOT alone caused a significant reduction in tumour size. This study confirms recent literature supporting the use of HBOT with and without conventional therapy <view study>